SCHEMBL19902396

SCHEMBL19902396

Cc1cc(F)cn2c(C(=O)N[C@H]3CC[C@H](c4n[nH]c(=O)c5ccccc54)CC3)cnc12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 3/20 0.43
ROCK1 Q13464 3/20 0.40
GRIN1 Q05586 2/20 0.38
GRIN2B Q13224 2/20 0.38
TGFBR1 P36897 2/20 0.37
TYK2 P29597 3/20 0.36
PDE4B Q07343 2/20 0.36
CSF1R P07333 1/20 0.35
PARP1 P09874 2/20 0.35
KDM4E B2RXH2 1/20 0.35
TSHR P16473 1/20 0.35
CREBBP Q92793 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
ABL1 P00519 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19902604 0.92 ROCK2 (0.40) ROCK2ROCK1TGFBR1TYK2PDE4B
SCHEMBL17452939 0.90 ROCK2 (0.56) ROCK2ROCK1GRIN1GRIN2BPARP1
SCHEMBL19902451 0.85 ROCK1 (0.44) ROCK2ROCK1TGFBR1CSF1RPARP1
SCHEMBL19902519 0.84 TGFBR1 (0.46) ROCK2ROCK1TGFBR1ABL1
SCHEMBL19902643 0.84 ROCK2 (0.38) ROCK2ROCK1PDE4BPARP1HSD17B10
SCHEMBL19902516 0.82 ROCK2 (0.43) ROCK2ROCK1TGFBR1TYK2PDE4B
SCHEMBL19902518 0.82 CSF1R (0.46) ROCK2ROCK1TGFBR1CSF1RPARP1
SCHEMBL19902368 0.82 ROCK1 (0.49) ROCK2ROCK1TGFBR1CSF1RPARP1
SCHEMBL17452922 0.81 ROCK2 (0.53) ROCK2ROCK1PARP1
SCHEMBL19902489 0.80 ROCK2 (0.40) ROCK2ROCK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 ROCK2 3/4885ROCK1 1/4885GRIN1 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.